Abstract
摘要
相似文献
1
The sources of innovation.创新的来源。
Psychopharmacol Bull. 1972 Apr;8(2):50-8.
2
The beginning of antimicrobial therapy: introduction of the sulfonamides and penicillins.抗菌治疗的开端：磺胺类药物和青霉素的引入。
J Infect Dis. 1972 Mar;125:Suppl:22-46. doi: 10.1093/infdis/125.supplement_1.s22.
3
Constraints on innovation in drug development and use.
Psychopharmacol Bull. 1972 Apr;8(2):43-50.
4
FDA principles on clinical investigations.美国食品药品监督管理局关于临床研究的原则
Psychopharmacol Bull. 1972 Apr;8(2):31-5.
5
Investigational and new drugs.
Psychopharmacol Bull. 1972 Apr;8(2):36-9.
6
Drug studies in children.
Pediatr Pharmacol (New York). 1980;1(1):7-14.
7
Pediatric drug testing enters infancy.
Nat Med. 2003 Jun;9(6):631. doi: 10.1038/nm0603-631a.
8
Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.
Ration Drug Ther. 1983 Jan;17(1):1-7.
9
Clinical trials from the industry viewpoint.
J Am Vet Med Assoc. 1972 Dec 1;161(11):1391-4.
10
The regulatory role of the United States Food and Drug Administration.
J Reprod Med. 1972 Apr;8(4):205-6.
引用本文的文献
1
The effects of external knowledge source heterogeneity on enterprise process and product innovation performance.外部知识源异质性对企业流程和产品创新绩效的影响。
PLoS One. 2020 Jun 12;15(6):e0234649. doi: 10.1371/journal.pone.0234649. eCollection 2020.
Zotero 插件